Tyra Biosciences Stock (NASDAQ:TYRA)
Previous Close
$15.39
52W Range
$10.60 - $29.60
50D Avg
$21.31
200D Avg
$19.25
Market Cap
$782.83M
Avg Vol (3M)
$313.64K
Beta
1.08
Div Yield
-
TYRA Company Profile
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
TYRA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GRCL | Gracell Biotechnologies Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| IKNA | Ikena Oncology, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| ERAS | Erasca, Inc. |
| CNTB | Connect Biopharma Holdings Limited |
| CCCC | C4 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| PHVS | Pharvaris N.V. |
| HOWL | Werewolf Therapeutics, Inc. |
| XLO | Xilio Therapeutics, Inc. |
| MOLN | Molecular Partners AG |
| RAPT | RAPT Therapeutics, Inc. |